title: Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis.
abstract: BACKGROUND
  Light chain amyloidosis is a rare plasma cell dyscrasia. Interphase fluorescence in situ hybridization (FISH) coupled to cytoplasmic staining of specific Ig (cIg-FISH) on bone marrow plasma cells has become well established in the initial evaluation of multiple myeloma, a related disorder. Little, however, is known about cytogenetic abnormalities in patients with light chain amyloidosis.
  
  
  METHODS
  We reviewed 56 patients with light chain amyloidosis who had cIg-FISH performed as part of their routine clinical testing using the standard screening panel employed in multiple myeloma at our institution.
  
  
  RESULTS
  Seventy percent of patients had abnormal cIg-FISH, with the most common abnormalities being IgH translocations [48%]--including t(11;14) [39%], and t(14;16) [2%]--and del13/del13q [30%]. No t(4;14) or deletions of 17p (p53) were observed. Patients with t(11;14) had the lowest levels of clonal plasma cells, and those with del13 had the highest. The risk of death for patients harboring the t(11;14) translocation was 2.1 (CI 1.04-6.4), which on multivariate analysis was independent of therapy.
  
  
  CONCLUSIONS
  Although preliminary, our data would suggest that cIg-FISH testing is important in patients with light chain amyloidosis and that t(11;14) is an adverse prognostic factor in these patients.
authors.affiliation: Divison of Hematology, Mayo Clinic, 200 First Street, S.W., Rochester, MN 55905, USA.
authors.forename: Alan H
authors.initials: AH
authors.lastname: Bryce
authors.forename: Rhett P
authors.initials: RP
authors.lastname: Ketterling
authors.forename: Morie A
authors.initials: MA
authors.lastname: Gertz
authors.forename: Martha
authors.initials: M
authors.lastname: Lacy
authors.forename: Ryan A
authors.initials: RA
authors.lastname: Knudson
authors.forename: Steven
authors.initials: S
authors.lastname: Zeldenrust
authors.forename: Shaji
authors.initials: S
authors.lastname: Kumar
authors.forename: Suzanne
authors.initials: S
authors.lastname: Hayman
authors.forename: Francis
authors.initials: F
authors.lastname: Buadi
authors.forename: Robert A
authors.initials: RA
authors.lastname: Kyle
authors.forename: Philip R
authors.initials: PR
authors.lastname: Greipp
authors.forename: John A
authors.initials: JA
authors.lastname: Lust
authors.forename: Stephen
authors.initials: S
authors.lastname: Russell
authors.forename: S Vincent
authors.initials: SV
authors.lastname: Rajkumar
authors.forename: Rafael
authors.initials: R
authors.lastname: Fonseca
authors.forename: Angela
authors.initials: A
authors.lastname: Dispenzieri
mesh_terms: D000328:Adult; D000368:Aged; D000686:Amyloidosis / Q000235:genetics* / Q000473:pathology / Q000628:therapy; D002880:Chromosomes, Human, Pair 11 / Q000235:genetics*; D002883:Chromosomes, Human, Pair 14 / Q000235:genetics*; D005260:Female; D006801:Humans; D007147:Immunoglobulin Light Chains / Q000235:genetics; D017404:In Situ Hybridization, Fluorescence / Q000379:methods / Q000706:statistics & numerical data; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D016016:Proportional Hazards Models; D014178:Translocation, Genetic
chemical_list: D007147:Immunoglobulin Light Chains